Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy

Yuki Eguchi; Tokiko Nakai; Motohiro Kojima; Masashi Wakabayashi; Naoya Sakamoto; Shingo Sakashita; Saori Miyazaki; Tetsuro Taki; Reiko Watanabe; Rurina Watanuki; Chisako Yamauchi; Tsuguo Iwatani; Toru Mukohara; Tatsuya Onishi; Genichiro Ishii

doi:10.1111/cas.15273

Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy

Yuki Eguchi, Tokiko Nakai, Motohiro Kojima, Masashi Wakabayashi, Naoya Sakamoto, Shingo Sakashita, Saori Miyazaki, Tetsuro Taki, Reiko Watanabe, Rurina Watanuki, Chisako Yamauchi, Tsuguo Iwatani, Toru Mukohara, Tatsuya Onishi, Genichiro Ishii

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple-negative breast cancer (TNBC) patients after NAC. We included 143 patients with TNBC treated with NAC. The ART at the maximum cut surface of the residual tumor was measured. We divided the patients into three groups: ART-0 (ART = 0 mm²), ART-low (0 mm² < ART ≤ 136mm²), and ART-high (ART > 136 mm²), and compared their clinicopathologic factors and prognosis. There were no significant differences in either recurrence-free survival (RFS) or overall survival (OS) between ART-0 and ART-low; however, the ART-high group had significantly shorter RFS and OS than the ART-0 and ART-low groups. Multivariate analysis showed that ART-0 and -low and ypN(−) were independent favorable prognostic factors for RFS. Groups with both ART-low and ypN(−) as well as those with ART-0 and ypN(−) showed significantly longer OS and RFS than the other groups (P <.05). Moreover, there was no significant difference in the RFS and OS between the ART-0 and ypN(−) groups and the ART-low and ypN(−) groups (P =.249 and P =.554, respectively). We concluded that ART is a candidate histopathological evaluation method for predicting the prognosis of TNBC patients treated with NAC. Furthermore, postoperative chemotherapy could be omitted in patients with ART-0 and ypN(−) (pathological complete response) and those with ART-low and ypN(−).

Original language	English
Pages (from-to)	1507-1518
Number of pages	12
Journal	Cancer Science
Volume	113
Issue number	4
DOIs	https://doi.org/10.1111/cas.15273
Publication status	Published - Apr 2022
Externally published	Yes

Keywords

breast neoplasm
evaluation criteria in solid tumors
neoadjuvant therapy
pathology

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/cas.15273

Cite this

Eguchi, Y., Nakai, T., Kojima, M., Wakabayashi, M., Sakamoto, N., Sakashita, S., Miyazaki, S., Taki, T., Watanabe, R., Watanuki, R., Yamauchi, C., Iwatani, T., Mukohara, T., Onishi, T., & Ishii, G. (2022). Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy. Cancer Science, 113(4), 1507-1518. https://doi.org/10.1111/cas.15273

Eguchi, Y, Nakai, T, Kojima, M, Wakabayashi, M, Sakamoto, N, Sakashita, S, Miyazaki, S, Taki, T, Watanabe, R, Watanuki, R, Yamauchi, C, Iwatani, T, Mukohara, T, Onishi, T & Ishii, G 2022, 'Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy', Cancer Science, vol. 113, no. 4, pp. 1507-1518. https://doi.org/10.1111/cas.15273

@article{a55935604d9246779d47d4b2d2ce7607,

title = "Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy",

abstract = "The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple-negative breast cancer (TNBC) patients after NAC. We included 143 patients with TNBC treated with NAC. The ART at the maximum cut surface of the residual tumor was measured. We divided the patients into three groups: ART-0 (ART = 0 mm2), ART-low (0 mm2 < ART ≤ 136mm2), and ART-high (ART > 136 mm2), and compared their clinicopathologic factors and prognosis. There were no significant differences in either recurrence-free survival (RFS) or overall survival (OS) between ART-0 and ART-low; however, the ART-high group had significantly shorter RFS and OS than the ART-0 and ART-low groups. Multivariate analysis showed that ART-0 and -low and ypN(−) were independent favorable prognostic factors for RFS. Groups with both ART-low and ypN(−) as well as those with ART-0 and ypN(−) showed significantly longer OS and RFS than the other groups (P <.05). Moreover, there was no significant difference in the RFS and OS between the ART-0 and ypN(−) groups and the ART-low and ypN(−) groups (P =.249 and P =.554, respectively). We concluded that ART is a candidate histopathological evaluation method for predicting the prognosis of TNBC patients treated with NAC. Furthermore, postoperative chemotherapy could be omitted in patients with ART-0 and ypN(−) (pathological complete response) and those with ART-low and ypN(−).",

keywords = "breast neoplasm, evaluation criteria in solid tumors, neoadjuvant therapy, pathology",

author = "Yuki Eguchi and Tokiko Nakai and Motohiro Kojima and Masashi Wakabayashi and Naoya Sakamoto and Shingo Sakashita and Saori Miyazaki and Tetsuro Taki and Reiko Watanabe and Rurina Watanuki and Chisako Yamauchi and Tsuguo Iwatani and Toru Mukohara and Tatsuya Onishi and Genichiro Ishii",

note = "Funding Information: Toru Mukohara received research funding from Daiichi‐Sankyo, Sysmex, MSD, Pfizer, Sanofi, and Chugai Pharmaceuticals. Genichiro Ishii received research funding from Daiichi‐Sankyo, Noile‐Immune Biotech, Takeda Pharmaceutical company, ONO Pharmaceutical Co., Ltd, and Sumitomo Dainippon Pharma. No conflict of interest for other authors. Funding Information: Japan Society for the Promotion of Science KAKENHI, Grant/Award Number: 18H15087 and 21H02931. Publisher Copyright: {\textcopyright} 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.",

year = "2022",

month = apr,

doi = "10.1111/cas.15273",

language = "English",

volume = "113",

pages = "1507--1518",

journal = "Cancer Science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy

AU - Eguchi, Yuki

AU - Nakai, Tokiko

AU - Kojima, Motohiro

AU - Wakabayashi, Masashi

AU - Sakamoto, Naoya

AU - Sakashita, Shingo

AU - Miyazaki, Saori

AU - Taki, Tetsuro

AU - Watanabe, Reiko

AU - Watanuki, Rurina

AU - Yamauchi, Chisako

AU - Iwatani, Tsuguo

AU - Mukohara, Toru

AU - Onishi, Tatsuya

AU - Ishii, Genichiro

N1 - Funding Information: Toru Mukohara received research funding from Daiichi‐Sankyo, Sysmex, MSD, Pfizer, Sanofi, and Chugai Pharmaceuticals. Genichiro Ishii received research funding from Daiichi‐Sankyo, Noile‐Immune Biotech, Takeda Pharmaceutical company, ONO Pharmaceutical Co., Ltd, and Sumitomo Dainippon Pharma. No conflict of interest for other authors. Funding Information: Japan Society for the Promotion of Science KAKENHI, Grant/Award Number: 18H15087 and 21H02931. Publisher Copyright: © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

PY - 2022/4

Y1 - 2022/4

N2 - The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple-negative breast cancer (TNBC) patients after NAC. We included 143 patients with TNBC treated with NAC. The ART at the maximum cut surface of the residual tumor was measured. We divided the patients into three groups: ART-0 (ART = 0 mm2), ART-low (0 mm2 < ART ≤ 136mm2), and ART-high (ART > 136 mm2), and compared their clinicopathologic factors and prognosis. There were no significant differences in either recurrence-free survival (RFS) or overall survival (OS) between ART-0 and ART-low; however, the ART-high group had significantly shorter RFS and OS than the ART-0 and ART-low groups. Multivariate analysis showed that ART-0 and -low and ypN(−) were independent favorable prognostic factors for RFS. Groups with both ART-low and ypN(−) as well as those with ART-0 and ypN(−) showed significantly longer OS and RFS than the other groups (P <.05). Moreover, there was no significant difference in the RFS and OS between the ART-0 and ypN(−) groups and the ART-low and ypN(−) groups (P =.249 and P =.554, respectively). We concluded that ART is a candidate histopathological evaluation method for predicting the prognosis of TNBC patients treated with NAC. Furthermore, postoperative chemotherapy could be omitted in patients with ART-0 and ypN(−) (pathological complete response) and those with ART-low and ypN(−).

AB - The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple-negative breast cancer (TNBC) patients after NAC. We included 143 patients with TNBC treated with NAC. The ART at the maximum cut surface of the residual tumor was measured. We divided the patients into three groups: ART-0 (ART = 0 mm2), ART-low (0 mm2 < ART ≤ 136mm2), and ART-high (ART > 136 mm2), and compared their clinicopathologic factors and prognosis. There were no significant differences in either recurrence-free survival (RFS) or overall survival (OS) between ART-0 and ART-low; however, the ART-high group had significantly shorter RFS and OS than the ART-0 and ART-low groups. Multivariate analysis showed that ART-0 and -low and ypN(−) were independent favorable prognostic factors for RFS. Groups with both ART-low and ypN(−) as well as those with ART-0 and ypN(−) showed significantly longer OS and RFS than the other groups (P <.05). Moreover, there was no significant difference in the RFS and OS between the ART-0 and ypN(−) groups and the ART-low and ypN(−) groups (P =.249 and P =.554, respectively). We concluded that ART is a candidate histopathological evaluation method for predicting the prognosis of TNBC patients treated with NAC. Furthermore, postoperative chemotherapy could be omitted in patients with ART-0 and ypN(−) (pathological complete response) and those with ART-low and ypN(−).

KW - breast neoplasm

KW - evaluation criteria in solid tumors

KW - neoadjuvant therapy

KW - pathology

UR - http://www.scopus.com/inward/record.url?scp=85125456798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125456798&partnerID=8YFLogxK

U2 - 10.1111/cas.15273

DO - 10.1111/cas.15273

M3 - Article

C2 - 35143092

AN - SCOPUS:85125456798

SN - 1347-9032

VL - 113

SP - 1507

EP - 1518

JO - Cancer Science

JF - Cancer Science

IS - 4

ER -

Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this